The Institute for Clinical and Economic Review (ICER) suggested in its latest report on Novartis’ siponimod for the treatment of secondary progressive multiple sclerosis (SPMS) that the drug “does not merit a unique role in therapy.”
According to a press release, the Midwest Comparative Effectiveness Public Advisory Council found that there was insufficient evidence to “demonstrate that siponimod is superior to the best supportive care for patients with non-active SPMS.”
“There is a large unmet need for effective treatments for progression in SPMS,” ICER CMO David Rind said in a statement. “Like other disease modifying therapies (DMTs), including the related drug fingolimod, siponimod has demonstrated the ability to reduce relapses in patients with relapsing forms of MS, but siponimod has not been proven to affect the disability progression independent of relapses that is the devastating hallmark of SPMS.”
To read the full press release, click here.
